Windlas Biotech (NSE:WINDLAS) EPS (Basic): ₹31.61 (TTM As of Mar. 2026)


NSE:WINDLAS Windlas Biotech Ltd NSE:WINDLAS
89 GF Score
Price ₹855.75
GF Value ₹936.27
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Windlas Biotech EPS (Basic)?

Windlas Biotech NSE:WINDLAS -0.19% 89 EPS (Basic) is ₹31.61 as of Mar. 2026. GuruFocus rates NSE:WINDLAS with a GF Score™ of 89/100 and a GF Value™ of ₹936.27 (Fairly Valued). The stock has 1 warning sign investors should review.

Windlas Biotech's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was ₹7.58. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹31.61.

Windlas Biotech's EPS (Diluted) for the three months ended in Mar. 2026 was ₹7.49. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹31.28.

Windlas Biotech's EPS without NRI for the three months ended in Mar. 2026 was ₹7.49. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 31.28.

During the past 12 months, Windlas Biotech's average EPS without NRIGrowth Rate was 8.20% per year. During the past 3 years, the average EPS without NRI Growth Rate was 16.50% per year. During the past 5 years, the average EPS without NRI Growth Rate was 13.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 8 years, Windlas Biotech's highest 3-Year average EPS without NRI Growth Rate was 40.40% per year. The lowest was 15.10% per year. And the median was 16.50% per year.

Windlas Biotech  (NSE:WINDLAS) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Windlas Biotech EPS (Basic) Related Terms

Windlas Biotech EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Windlas Biotech's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Windlas Biotech EPS (Basic) Chart

Windlas Biotech Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EPS (Basic)
Get a 7-Day Free Trial 18.58 19.70 27.97 29.19 31.60

Windlas Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.77 8.43 8.48 7.12 7.58
NSE:WINDLAS
89GF Score
Windlas Biotech Ltd NSE:WINDLAS
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Windlas Biotech EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Windlas Biotech's Basic EPS for the fiscal year that ended in Mar. 2026 is calculated as

Basic EPS (A: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(664.56-0)/21.030
=31.60

Windlas Biotech's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(159.9-0)/21.095
=7.58

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹31.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of ₹31.61 mean?
Windlas Biotech (NSE:WINDLAS) has a EPS (Basic) of ₹31.61 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Windlas Biotech and its competitors.
Is Windlas Biotech's EPS (Basic) too high?
Windlas Biotech's current EPS (Basic) is ₹31.61. Overall, Windlas Biotech has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's EPS (Basic) compare to ZTS?
Windlas Biotech's EPS (Basic) of ₹31.61 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Windlas Biotech and its competitors. Windlas Biotech's current EPS (Basic) is ₹31.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Fairly Valued. The stock's GF Value™ is ₹936.27, compared to a current price of ₹855.75 — trading 8.6% below its estimated fair value. The current EPS (Basic) is ₹31.61. Windlas Biotech's overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current EPS (Basic) is ₹31.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?

Based on GuruFocus' analysis, Windlas Biotech stock appears to be undervalued. The current stock price of ₹855.75 is trading 8.6% below its estimated GF Value™ of ₹936.27. GuruFocus considers Windlas Biotech to be Fairly Valued.

Key valuation signals for NSE:WINDLAS:

  • EPS (Basic): ₹31.61
  • GF Value™: ₹936.27 vs. price of ₹855.75 (8.6% below fair value)
  • GF Score™: 89/100 with 1 warning sign

No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Windlas Biotech Business Description

Other Exchanges 543329:India
Address Golf Course Extension Road, 705-706, Vatika Professional Point, Sector-66, Gurgaon, HR, IND, 122 001
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
89GF Score

Get the complete analysis for NSE:WINDLAS

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹855.75
Price
₹936.27
GF Value